Would you favor starting with pembrolizumab or chemotherapy for a metastatic MSI-high pancreatic ductal adenocarcinoma?
Would your recommendation change in a patient having pain from disease and you wanted a quick response?
Community PollStarted
What is your preferred first line treatment for MSI-High PDAC?
36 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic, Rochester
Answered on
This is a great question. MSI-H status in PDAC is rare, about 1-2% of all PDAC (Luchini et al., PMID 32350089). Marabelle and colleagues published one of the initial studies using pembrolizumab in MSI-H solid tumors showing a response rate of 18.2% among PDAC (22 patients) with a median duration of ...
Join for free or sign in to see the full answer